![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2022
Anzahl der Publikationen: 1
2022
Balanescu, Andra-Rodica 
ORCID: https://orcid.org/0000-0003-0688-9173; Citera, Gustavo ORCID: https://orcid.org/0000-0002-3724-1874; Pascual-Ramos, Virginia ORCID: https://orcid.org/0000-0002-7368-498X; Bhatt, Deepak L. ORCID: https://orcid.org/0000-0002-1278-6245; Connell, Carol A.; Gold, David; Chen, All-Shine; Sawyerr, Gosford; Shapiro, Andrea B.; Pope, Janet E. ORCID: https://orcid.org/0000-0003-1479-5302 und Schulze-Koops, Hendrik ORCID: https://orcid.org/0000-0002-1681-491X
(2022):
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
In: Annals of the Rheumatic Diseases, Bd. 81, Nr. 11: S. 1491-1503
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-0688-9173; Citera, Gustavo ORCID: https://orcid.org/0000-0002-3724-1874; Pascual-Ramos, Virginia ORCID: https://orcid.org/0000-0002-7368-498X; Bhatt, Deepak L. ORCID: https://orcid.org/0000-0002-1278-6245; Connell, Carol A.; Gold, David; Chen, All-Shine; Sawyerr, Gosford; Shapiro, Andrea B.; Pope, Janet E. ORCID: https://orcid.org/0000-0003-1479-5302 und Schulze-Koops, Hendrik ORCID: https://orcid.org/0000-0002-1681-491X
(2022):
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
In: Annals of the Rheumatic Diseases, Bd. 81, Nr. 11: S. 1491-1503
[PDF, 1MB]